CI-1021
| CI-1021 | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
CI-1021 is a chemical compound that has been investigated for its potential use in the treatment of various medical conditions. It is primarily known as a selective antagonist of the neurokinin-1 receptor (NK1 receptor), which is involved in the modulation of pain and inflammation, as well as the regulation of mood and anxiety.
Pharmacology[edit]
CI-1021 functions by blocking the action of substance P, a neuropeptide that binds to the NK1 receptor. Substance P is associated with the transmission of pain signals and the regulation of emotional responses. By inhibiting this interaction, CI-1021 may reduce pain and have anxiolytic effects.
Clinical Research[edit]
Research into CI-1021 has focused on its potential applications in treating conditions such as chronic pain, depression, and anxiety disorders. However, as of the latest updates, CI-1021 has not been approved for clinical use, and its development status remains uncertain.
Mechanism of Action[edit]
The NK1 receptor is a G-protein coupled receptor that, when activated by substance P, initiates a cascade of intracellular events leading to the sensation of pain and the modulation of mood. CI-1021, by acting as an antagonist, prevents these effects by blocking the receptor.
Potential Applications[edit]
- Pain Management: CI-1021 has been studied for its potential to alleviate chronic pain conditions by interfering with the pain signaling pathways.
- Psychiatric Disorders: Due to its effects on mood regulation, CI-1021 has been explored as a treatment for depression and anxiety.
Safety and Efficacy[edit]
The safety profile of CI-1021 has been evaluated in preclinical studies, but comprehensive clinical trials are necessary to establish its efficacy and safety in humans. Potential side effects and long-term impacts remain areas of active research.
Also see[edit]
| Receptor Antagonists | |
|---|---|
| Receptor Type | Example Antagonists |
| Adrenergic receptor | Propranolol, Prazosin |
| Cholinergic receptor | Atropine, Scopolamine |
| Dopamine receptor | Haloperidol, Clozapine |
| Histamine receptor | Ranitidine, Diphenhydramine |
| Serotonin receptor | Ondansetron, Risperidone |
| Glutamate receptor | Memantine, Ketamine |
| GABA receptor | Flumazenil, Bicuculline |
| Opioid receptor | Naloxone, Naltrexone |
| Angiotensin receptor | Losartan, Valsartan |
| Pharmacology | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
